BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 30117144)

  • 1. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Canaani J; Labopin M; Huang XJ; Ciceri F; Van Lint MT; Bruno B; Santarone S; Diez-Martin JL; Blaise D; Chiusolo P; Wu D; Mohty M; Nagler A
    Br J Haematol; 2018 Nov; 183(3):411-420. PubMed ID: 30117144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
    Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Canaani J; Labopin M; Huang XJ; Arcese W; Ciceri F; Blaise D; Irrera G; Corral LL; Bruno B; Santarone S; Van Lint MT; Vitek A; Esteve J; Mohty M; Nagler A
    Am J Hematol; 2018 Jun; 93(6):736-744. PubMed ID: 29498106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Filippini Velázquez G; Labopin M; Tischer J; Raiola AM; Angelucci E; Kulagin AD; Galieni P; Bermúdez A; Bulabois CE; Kröger N; Díez-Martín JL; Kwon M; Nagler A; Schmid C; Ciceri F; Mohty M
    Bone Marrow Transplant; 2023 Aug; 58(8):907-915. PubMed ID: 37160941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
    Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
    Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Kharfan-Dabaja MA; Labopin M; Brissot E; Kroger N; Finke J; Ciceri F; Deconinck E; Blaise D; Chevallier P; Gramatzki M; Ganser A; Stelljes M; Edinger M; Savani B; Ruggeri A; Sanz J; Nagler A; Mohty M
    Br J Haematol; 2021 May; 193(3):592-601. PubMed ID: 33838047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
    Helbig G; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kopińska A; Boral K; Grygoruk-Wiśniowska I; Stachowicz M; Karolczyk A
    Ann Hematol; 2020 Aug; 99(8):1845-1853. PubMed ID: 32333156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
    Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
    Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Ye Y; Labopin M; Gérard S; Yakoub-Agha I; Blau IW; Aljurf M; Forcade E; Gedde-Dahl T; Burns D; Vydra J; Halahleh K; Hamladji RM; Bazarbachi A; Nagler A; Brissot E; Li L; Luo Y; Zhao Y; Ciceri F; Huang H; Mohty M; Gorin NC
    Am J Hematol; 2024 Jul; 99(7):1290-1299. PubMed ID: 38654658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
    Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
    Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
    Maffini E; Labopin M; Beelen DW; Kroeger N; Arat M; Wilson KMO; Bay JO; Ganser A; Martin H; Passweg J; Kottaridis PD; Yakoub-Agha I; Porras RP; Wagner EM; Esteve J; Lanza F; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Oct; 57(10):1556-1563. PubMed ID: 35835997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
    Lorentino F; Labopin M; Bernardi M; Ciceri F; Socié G; Cornelissen JJ; Esteve J; Ruggeri A; Volin L; Yacoub-Agha I; Craddock C; Passweg J; Blaise D; Gedde-Dahl T; Poiani M; Fegueux N; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1236-1244. PubMed ID: 30058714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.